Drug
Dsp 1349m
Dsp 1349m: highest development phase Phase 1, developed by Sumitomo Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| DSP-1349M NCT03627195 | Phase 1 | Schizophrenia |
Latest
No recent events.
Follow Dsp 1349m on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.